{
    "id": 15093,
    "fullName": "SRGAP3 - RAF1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "SRGAP3-RAF1 results from the fusion of SRGAP3 and RAF1, demonstrating constitutive Raf1 kinase activity, active downstream Mapk signaling and the ability to transform cells in culture, and confers resistance to first and second generation RAF inhibitors in culture (PMID: 19363522, PMID: 28806393). SRGAP3-RAF1 has been identified in pilocytic astrocytoma (PMID: 17086101, PMID: 19363522).",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                },
                {
                    "id": 16172,
                    "pubMedId": 17086101,
                    "title": "Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17086101"
                },
                {
                    "id": 4076,
                    "pubMedId": 19363522,
                    "title": "Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19363522"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 9901,
        "geneSymbol": "SRGAP3",
        "terms": [
            "SRGAP3",
            "ARHGAP14",
            "MEGAP",
            "SRGAP2",
            "WRP"
        ]
    },
    "variant": "SRGAP3 - RAF1",
    "createDate": "12/09/2015",
    "updateDate": "09/05/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 5894,
                "geneSymbol": "RAF1",
                "terms": [
                    "RAF1",
                    "c-Raf",
                    "CMD1NN",
                    "CRAF",
                    "NS5",
                    "Raf-1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 18428,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 treatment resulted in paradoxical activation of the MAPK pathway and increased soft agar growth in transformed cells expressing SRGAP3-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18437,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited MAPK and PI3K signaling, resulted in inhibition of soft agar growth in transformed cells expressing SRGAP3-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18433,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 treatment resulted in paradoxical activation of the MAPK pathway and increased soft agar growth in transformed mouse astrocytes expressing SRGAP3-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18432,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX4720 treatment resulted in paradoxical activation of the MAPK pathway and increased soft agar growth in transformed mouse astrocytes expressing SRGAP3-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 1060,
                "therapyName": "PLX4720",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18436,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY3009120 inhibited MAPK and PI3K signaling, resulted in inhibition of soft agar growth in transformed mouse astrocytes expressing SRGAP3-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18444,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) and Afinitor (everolimus) combination treatment inhibited MAPK and PI3K signaling, resulted in suppression of soft agar growth in transformed cells expressing SRGAP3-RAF1 in culture, and prolonged tumor suppression in xenograft models (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 1271,
                "therapyName": "Everolimus + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18429,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PLX8394 treatment resulted in paradoxical activation of the MAPK pathway and increased soft agar growth in transformed cells expressing SRGAP3-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 1041,
                "therapyName": "PLX8394",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18441,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation and soft agar growth in transformed mouse astrocytes expressing SRGAP3-RAF1 in culture (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 3069,
                "name": "astrocytoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18442,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) inhibited Erk phosphorylation and soft agar growth in transformed cells expressing SRGAP3-RAF1 in culture, but only delayed tumor growth in xenograft models (PMID: 28806393).",
            "molecularProfile": {
                "id": 15349,
                "profileName": "SRGAP3 - RAF1"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15708,
                    "pubMedId": 28806393,
                    "title": "CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28806393"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15349,
            "profileName": "SRGAP3 - RAF1",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}